Brian Czerniecki, Ph.D., M.D.

Funded by Hooters of America LLC

Participation in breast clinical trials ranges from about a low of 0.5% to a high of 2-3% in patients with breast cancer.  The majority of these trials have involved surgery, chemotherapy, and radiation all with substantial side effects but even when the safety profile is minimal these trials have not appealed to patients. More recently it has become clear that the immune response plays a large part in determining how well someone does when diagnosed with breast cancer. It is even possible now to utilize that immune response in the blood to predict response to therapy and predict recurrence. This means that the immune response can be used to predict cancer development, predict response to therapy and possibly improve outcomes by manipulating the immune response using immune stimulants, vaccines, cell therapies, and adoptive cell strategies to bolster the immune response to prevent recurrence. The purpose of this project is to develop an educational program in the burgeoning field of breast immunoncology for breast cancer oncologists and other physicians, patient advocates, patients and care givers to improve awareness about the immune response in breast cancer and how we can use the immune response to optimize our current therapies and where additional immune manipulations will improve outcomes. Our goal is to increase awareness about clinical trials in breast immunotherapy that ultimately increase patient accrual on studies and more rapidly move these promising modalities to clinically useful treatments for all patients with breast cancer. 

Location: Moffitt Cancer Center -
Proposal: Educating Providers, Advocates, and Patients about Immunotherapy in Breast Cancer to Enhance Clinical Trial Participation
Mailing List Mailing List
Close Mailing List